AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
57.51
+0.74 (1.30%)
Jun 18, 2026, 4:00 PM EDT - Market closed
AnaptysBio Employees
AnaptysBio had 104 employees as of December 31, 2025. The number of employees decreased by 32 or -23.53% compared to the previous year.
Employees
104
Change (1Y)
-32
Growth (1Y)
-23.53%
Revenue / Employee
$2,234,500
Profits / Employee
-$257,567
Market Cap
1.67B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 104 | -32 | -23.53% | 104 | 0 |
| Dec 31, 2024 | 136 | 19 | 16.24% | 136 | 0 |
| Dec 31, 2023 | 117 | 21 | 21.88% | 117 | 0 |
| Dec 31, 2022 | 96 | -6 | -5.88% | 96 | 0 |
| Dec 31, 2021 | 102 | 8 | 8.51% | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| AbCellera Biologics | 562 |
| Syndax Pharmaceuticals | 298 |
| UroGen Pharma | 298 |
| Zymeworks | 243 |
| Capricor Therapeutics | 231 |
| Precigen | 160 |
| Innoviva | 159 |
ANAB News
- 9 days ago - AnaptysBio assumed with a Buy at H.C. Wainwright - TheFly
- 5 weeks ago - AnaptysBio price target raised to $90 from $85 at Leerink - TheFly
- 5 weeks ago - AnaptysBio price target raised to $76 from $60 at UBS - TheFly
- 5 weeks ago - AnaptysBio price target raised to $75 from $63 at Barclays - TheFly
- 5 weeks ago - AnaptysBio reports Q1 EPS ($1.84), consensus (75c) - TheFly
- 5 weeks ago - Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - AnaptysBio Earnings release: Q1 2026 - Filings
- 5 weeks ago - AnaptysBio Quarterly report: Q1 2026 - Filings